Sanders et al. reported that RH-Δcps treatment significantly enhances infiltrating CD4+ and CD8+ T-cell activation and elevates the number of circulating tumor-specific T cells in the TME in pancreatic cancer patients. The gene discussed is CD8A; the disease is neoplasm.